<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Tiaprofenic acid</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01600</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Tiaprofenic acid is a non-steroidal anti-inflammatory drug of the arylpropionic acid (profen) class, used to treat pain, especially arthritic pain.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01600/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01600/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01600.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01600.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01600.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01600.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01600.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01600">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>2-(5-Benzoyl-thiophen-2-yl)-propionic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>5-Benzoyl-alpha-methyl-2-thiopheneacetic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Acide tiaprofenique</td><td>French</td><td>INN</td></tr><tr><td>Acido tiaprofenico</td><td>Spanish</td><td>INN</td></tr><tr><td>Acidum tiaprofenicum</td><td>Latin</td><td>INN</td></tr><tr><td>Tiaprofens&#228;ure</td><td>German</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Surgam</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Surgam SR</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Surgamyl</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-inflammatory-agents-non-steroidal">Anti-Inflammatory Agents, Non-Steroidal</a></li></ul></td></tr><tr><th>CAS number</th><td>33005-95-7</td></tr><tr><th>Weight</th><td>Average: 260.308<br>Monoisotopic: 260.05071494</td></tr><tr><th>Chemical Formula</th><td>C<sub>14</sub>H<sub>12</sub>O<sub>3</sub>S</td></tr><tr><th>InChI Key</th><td>GUHPRPJDBZHYCJ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C14H12O3S/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10/h2-9H,1H3,(H,16,17)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-(5-benzoylthiophen-2-yl)propanoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Acetophenones</td></tr><tr><th>Direct parent</th><td>Acetophenones</td></tr><tr><th>Alternative parents</th><td>Thiophene Carboxylic Acids and Derivatives; Benzoyl Derivatives; Ketones; Enolates; Carboxylic Acids; Polyamines</td></tr><tr><th>Substituents</th><td>benzoyl; thiophene carboxylic acid or derivative; thiophene; ketone; polyamine; carboxylic acid; enolate; carboxylic acid derivative; carbonyl group</td></tr><tr><th>Classification description</th><td>This compound belongs to the acetophenones. These are organic compounds containing the acetophenone structure.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Tiaprofenic acid is used to treat pain, especially arthritic pain.</td></tr><tr><th>Pharmacodynamics</th><td>Tiaprofenic acid is a non-steroidal anti-inflammatory drug of the arylpropionic acid (profen) class, used to treat pain, especially arthritic pain. The typical adult dose is 300mg twice daily. It is not recommended in children.</td></tr><tr><th>Mechanism of action</th><td>Tiaprofenic acid belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). It works by blocking the production of a chemical (prostaglandin) which the body produces in response to injury or certain diseases. This prostaglandin would otherwise go on to cause swelling, pain and inflammation.</td></tr><tr><th>Absorption</th><td>Bioavailability is 90% following oral administration.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic (10%). Sparingly metabolised in the liver to two inactive metabolites.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>1.5-2.5 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9927</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9289</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6039</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7298</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9534</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9664</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8998</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.6293</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9226</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.8098</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8607</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8958</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9526</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8682</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9398
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7568
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.7714
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.1892 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9869
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9716
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule, extended release</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Increased risk of bleeding. </td></tr><tr><td><a href="/drugs/DB00945">Acetylsalicylic acid</a></td><td>Increased risk of gastrointestinal bleeding. </td></tr><tr><td><a href="/drugs/DB00233">Aminosalicylic Acid</a></td><td>Increased risk of gastrointestinal bleeding. </td></tr><tr><td><a href="/drugs/DB01432">Cholestyramine</a></td><td>The bile acid sequestrant, Cholestyramine resin, may reduce Tiaprofenic acid absorption and therapeutic effect.</td></tr><tr><td><a href="/drugs/DB00215">Citalopram</a></td><td>Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. </td></tr><tr><td><a href="/drugs/DB00930">Colesevelam</a></td><td>The bile acid sequestrant, Colesevelam, may reduce Tiaprofenic acid absorption and therapeutic effect.</td></tr><tr><td><a href="/drugs/DB00375">Colestipol</a></td><td>The bile acid sequestrant, Colestipol, may reduce Tiaprofenic acid absorption and therapeutic effect.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Tiaprofenic acid may increase the nephrotoxicity and/or the serum concentration of cyclosporine. Consider altnerate therapy or monitor for increased cyclosporine concentrations and nephrotoxicity during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01175">Escitalopram</a></td><td>Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. </td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. </td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. </td></tr><tr><td><a href="/drugs/DB01381">Ginkgo biloba</a></td><td>Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.</td></tr><tr><td><a href="/drugs/DB01404">Ginseng</a></td><td>Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds.</td></tr><tr><td><a href="/drugs/DB00465">Ketorolac</a></td><td>Concomitant therapy is contraindicated due to the risk of synergistic NSAID toxicity.</td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>Tiaprofenic acid may increase the therapeutic/adverse effects of Lithium by increasing Lithium serum concentrations. Monitor for changes in the therapeutic/adverse effects of Lithium if Tiaprofenic acid is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>Tiaprofenic acid may decrease renal excretion of methotrexate. Consider alternate therapy or monitor for methotrexate toxicity.</td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. </td></tr><tr><td><a href="/drugs/DB00642">Pemetrexed</a></td><td>Tiaprofenic acid may decrease Pemetrexed excretion. Tiaprofenic acid should not be used around the time when Pemetrexed is administered. </td></tr><tr><td><a href="/drugs/DB01399">Salsalate</a></td><td>Increased risk of gastrointestinal bleeding. </td></tr><tr><td><a href="/drugs/DB01104">Sertraline</a></td><td>Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. </td></tr><tr><td><a href="/drugs/DB00966">Telmisartan</a></td><td>Concomitant use of Telmisartan and Tiaprofenic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. </td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>The NSAID, Tiaprofenic acid, may antagonize the antihypertensive effect of Timolol.</td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>The NSAID, Tiaprofenic acid, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Tiaprofenic acid is initiated, discontinued or dose changed.  </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Tiaprofenic acid. Monitor for increased bleeding during concomitant thearpy. </td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The antiplatelet effects of tiaprofenic acid may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Take with food.</li></ul></td></tr></tbody></table>